CERETEC Drug Patent Profile
✉ Email this page to a colleague
When do Ceretec patents expire, and when can generic versions of Ceretec launch?
Ceretec is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in CERETEC is technetium tc-99m exametazime kit. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the technetium tc-99m exametazime kit profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CERETEC?
- What are the global sales for CERETEC?
- What is Average Wholesale Price for CERETEC?
Summary for CERETEC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| Clinical Trials: | 2 |
| Patent Applications: | 41 |
| Drug Prices: | Drug price information for CERETEC |
| What excipients (inactive ingredients) are in CERETEC? | CERETEC excipients list |
| DailyMed Link: | CERETEC at DailyMed |
Recent Clinical Trials for CERETEC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Kentucky | Phase 2 |
| Norton Healthcare | Phase 2 |
| Thomas Hatschek | Phase 2 |
Pharmacology for CERETEC
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Radiopharmaceutical Activity |
US Patents and Regulatory Information for CERETEC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | CERETEC | technetium tc-99m exametazime kit | INJECTABLE;INJECTION | 019829-001 | Dec 30, 1988 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CERETEC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | CERETEC | technetium tc-99m exametazime kit | INJECTABLE;INJECTION | 019829-001 | Dec 30, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | CERETEC | technetium tc-99m exametazime kit | INJECTABLE;INJECTION | 019829-001 | Dec 30, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CERETEC
See the table below for patents covering CERETEC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 0123504 | COMPLEXES OF TECHNETIUM-99M WITH ALKYLENE AMINE OXIMES | ⤷ Sign Up |
| Japan | H06184078 | COMPLEX OF TECHNETIUM 99 M WITH PROPYLENEAMINE OXIME | ⤷ Sign Up |
| Germany | 3687467 | ⤷ Sign Up | |
| Canada | 1252481 | COMPLEXES DE TECHNETIUM-99 AVEC DES OXIMES DE PROPYLENE-AMINE (COMPLEXES OF TECHNETIUM-99M WITH PROPYLENE AMINE OXIMES) | ⤷ Sign Up |
| Finland | 841622 | ⤷ Sign Up | |
| Czechoslovakia | 271306 | METHOD OF 99M TECHNETIUM'S LIPOPHILE MACROCYCLIC COMPLEXES PRODUCTION | ⤷ Sign Up |
| Finland | 78706 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CERETEC
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1178838 | 300736 | Netherlands | ⤷ Sign Up | PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
